Advertisement
Substances that cause cancer are called carcinogens. Familiar examples include tobacco smoke, radon, asbestos and diesel engine exhaust.
To protect the health of the public, national and international health agencies evaluate many new and existing chemicals to determine if they are likely to be carcinogens in a process called cancer hazard identification.
If agencies judge the chemicals to be carcinogenic, they conduct further assessments to determine the level of risk, and legislators may put regulations in place to limit, or completely halt, the production and use of these chemicals.
Related Articles
Advertisement
How do chemicals cause cancer? The mechanisms behind how toxic chemicals can lead to cancer are complex.
After a person is exposed to a carcinogen, the chemical is generally absorbed into the body and distributed into different tissues. Once the chemical has moved into the cells, it often undergoes chemical reactions that convert it into other forms.
The products of these reactions can directly or indirectly affect the cell’s genes. Altering genes, which contain the cell’s instructions on how to produce specific molecules, or the processes that regulate them can ultimately result in dysfunctional cells if the genetic damage isn’t repaired. These cells don’t respond normally to cellular signals and can grow and divide at abnormal rates, which are characteristic features of cancer cells.
How are chemicals classified for carcinogenicity? To help safeguard the public and reduce the incidence of cancer, several agencies have developed procedures to classify and categorise chemicals based on their potential to be carcinogenic.
Among them are the International Agency for Research on Cancer, or IARC Monographs; the National Toxicology Program, or NTP; and the U.S. Environmental Protection Agency, or EPA. In general, these agencies examine a critical question: How strong is the evidence that a substance causes cancer or biological changes that could be related to cancer in people? Understanding the procedures used to answer this question can help with interpreting the decisions these agencies make.
The procedures used by the IARC – because of its long history, credibility and strong international reputation – provide a good example of how this process works. It’s designed to be transparent and minimize bias, spanning over a year from selecting a chemical for evaluation to its final classification.
In this process, the IARC selects and invites a panel of scientific experts on the chemical to be evaluated. The panel does not conduct new research on its own, but carefully reviews all available papers in the scientific literature on the chemical’s carcinogenicity in cell and bacterial cultures, animals and people.
To assess the strength of the evidence, the panel carefully considers the number of studies that are available and the consistency of the results, as well as the scientific quality and relevance of each study to cancer in people.
After discussing and deliberating on the results, the panel makes a final consensus classification. This classification places the chemical into one of four groups: Group 1 indicates that the chemical is carcinogenic to people, Group 2A that it is probably carcinogenic to people, Group 2B that it is possibly carcinogenic to people, and Group 3 that it is not classifiable.
A Group 3 classification does not indicate that the compound is not carcinogenic, but rather that the panel could not draw a conclusion about whether there is a causal link between the chemical and cancer from available studies. For example, exposure to several chemicals can make it unclear which ones are responsible for a later cancer diagnosis.
During its 50-year history, the IARC has evaluated and classified over 1,000 chemicals and other hazards. Many of these classifications have had broad societal implications, such as those for tobacco smoke, ambient air pollution, diesel engine exhaust and processed meat.
All were classified as Group 1, or confirmed to be carcinogenic to humans. Electromagnetic radiation emitted by mobile phones was classified as Group 2B, or possibly carcinogenic, and red meat was classified as Group 2A, or probably carcinogenic.
Though they haven’t directly led to any regulations, these classifications have motivated additional scientific studies. While the IARC can advise regulators, it’s up to countries to implement policies.
It is important to note that classifications do not indicate the size of the risk but are important in supporting health agencies worldwide as they implement actions to limit exposures to known, probable and possible carcinogens. In 2020, when the IARC classified opium consumption as Group 1, or carcinogenic to humans, this led the government of Iran to implement policies to reduce opium addiction in the country.
Controversies in carcinogenicity classifications Though classifications from the IARC are based on robust scientific evidence, some have proved to be controversial.
For instance, in 2015, the IARC evaluated the carcinogenicity of glyphosate, a widely used weedkiller found in products like Roundup, which is produced by Monsanto. A panel of 17 experts from 11 countries systematically reviewed results from over 1,000 scientific studies and classified glyphosate as “probably carcinogenic to humans,” or Group 2A.
Owing to its widespread usage and multibillion-dollar market value, a cancer classification decision for glyphosate has significant potential financial and legal consequences. Following its evaluation, the IARC received support from many regulatory and scientific bodies but was criticised by others. Other agencies, including the EPA, have seen similar controversies and politicisation of their hazard identifications and regulatory decisions.
I believe that agencies like the IARC play a critical role in evaluating the health effects of certain chemicals and in reducing exposure to potential carcinogens. Helping people better understand how these agencies evaluate chemicals can go a long way to ensure transparency and help protect environmental and public health.
By Brad Reisfeld, Professor of Chemical and Biological Engineering, Colorado State University for The Conversation